GSK On Track For Six Regulatory Submissions In The Second Half
R&D President Hal Barron outlined progress reenergizing GSK's pharma pipeline and highlighted the key milestones ahead in 2019 during the company's second quarter call.
You may also be interested in...
The company filed an sNDA with the US FDA for the triple combination, hoping to expand its current COPD indication to also include asthma.
GSK has more than doubled its oncology pipeline since July 2018, and the company's CEO thinks smaller deals and a new site combining R&D and manufacturing will enable its progress to continue.
Industry CEOs expressed reservations about the US drug pricing legislation in the Senate, but said they support reforms that will impact patient affordability, during Q2 calls.